NDA 020973 · Waylis Therap
Aciphex
Rabeprazole Sodium · Oral
NovelLast checked: Nov 20, 2026Latest source record: Jul 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Aug 19, 1999
Approved uses
4
Original approval plus efficacy supplements
Registered trials
260
41 Phase 3, 12 recruiting
FAERS reports
27,290
21,997 serious, 3,391 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 27, 2026.
ACIPHEX delayed-release tablets is a proton pump inhibitor (PPI) indicated in adults for: Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) ( 1.1 ). Maintenance of Healing of Erosive or Ulcerative GERD ( 1.2 ). Treatment of Symptomatic GERD ( 1.3 ). Healing of Duodenal Ulcers ( 1.4 ). Helicobacter pylori Eradication to Reduce Risk of Duodenal Ulcer Recurrence ( 1.5 ). Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome ( 1.6 ). In adolescent patients 12 years of age and older for: Short-term Treatment of Symptomatic GERD ( 1.7 ). 1.1 Healing of Erosive or Ulcerative GERD in Adults ACIPHEX delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of ACIPHEX may be considered. 1.2 Maintenance of Healing of Erosive or Ulcerative GERD in Adults ACIPHEX delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance). Controlled studies do not extend beyond 12 months. 1.3 Treatment of Symptomatic GERD in Adults ACIPHEX delayed-release tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults for up to 4 weeks. 1.4 Healing of Duodenal Ulcers in Adults ACIPHEX delayed-release tablets are indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks. 1.5 Helicobacter pylori Eradication to Reduce the Risk of Duodenal...
Mechanism: Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H 2 -receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H + , K + ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 30, 2008 Supplement 22 · Efficacy LetterPediatric Medical ReviewPediatric Clinical Pharmacology Review
- Nov 8, 2002 Supplement 13 · Efficacy ReviewLetterLabel
- Feb 12, 2002 Supplement 9 · Efficacy LabelReviewLetter
- Aug 19, 1999 Original approval · Type 1 - New Molecular Entity Other Important Information from FDAPediatric Statistical ReviewPediatric Clinical Pharmacology Review
2 products under this application
- ACIPHEX · RABEPRAZOLE SODIUM 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, DELAYED RELEASE, ORAL · Discontinued
- ACIPHEX · RABEPRAZOLE SODIUM 20MG · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Rabeprazole" as an intervention, any sponsor and status, largest first.
- Helicobacter Pylori Eradication and Follow-upStatus unknown
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05061732 · 4,447 participants (planned) · Start Sep 30, 2021 · Primary completion Jun 30, 2026
Drug: Rabeprazole; Bismuth potassium citrate and 7 more · For: Helicobacter Pylori Infection
Sites: Shanghai, China
- Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic TherapyPivotal-lookingRecruiting
Duk-Woo Park, MDAcademic, hospital or other
NCT04416581 · 3,320 participants (planned) · Start May 12, 2021 · Primary completion Dec 31, 2027
Drug: PPI; P-CAB 50 · For: Coronary Artery Disease; Percutaneous Coronary Intervention; Acute Coronary Syndrome and 1 more
Sites: Anyang, South Korea; Bucheon-si, South Korea; Busan, South Korea · 45 sites in all
- Prophylaxis for Aspiration of Gastric Contents.Pivotal-lookingCompleted
King Saud UniversityAcademic, hospital or other
NCT02703896 · 1,920 participants · Start Jan 2012 · Primary completion Jan 2012
Drug: Drug either PPIS or H2RA and prokinetics · For: Pulmonary Aspiration of Gastric Contents
- Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori EradicationPivotal-lookingStatus unknown
Xijing Hospital of Digestive DiseasesAcademic, hospital or other
NCT06168214 · 1,404 participants (planned) · Start Sep 4, 2023 · Primary completion Nov 25, 2024
Drug: Rabeprazloe+bismuth+amoxicillin+clarithromycin; Vonoprazan+amoxicillin+clarithromycin 14 days and 7 more · For: the Eradication Rates of Helicobacter Pylori
Sites: Xi'an, China
- Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)Pivotal-lookingCompleted
Eisai Inc.Eisai
NCT00658632 · 1,397 participants · Start Feb 2008 · Primary completion Apr 2009
Drug: Rabeprazole sodium; Esomeprazole · For: Gastroesophageal Reflux Disease (GERD)
Sites: Huntsville, Alabama; Tucson, Arizona; Little Rock, Arkansas · 85 sites in all
Janssen-Cilag Pty LtdJohnson & Johnson (Janssen) (JNJ)
NCT00464308 · 1,392 participants · Start Nov 2006 · Primary completion May 2008
Drug: Esomeprazole; Rabeprazole and 1 more · For: Gastro-oesophageal Reflux
Sites: Belconnen, Australia; Bondi Junction, Australia; Brookvale, Australia · 25 sites in all
- Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)Pivotal-lookingCompleted
Eisai Inc.Eisai
NCT00658775 · 1,069 participants · Start Feb 2008 · Primary completion Sep 2009
Drug: Rabeprazole sodium; Esomeprazole · For: Gastroesophageal Reflux Disease (GERD)
Sites: Moline, Illinois; La Plata, Argentina; Buenos Aires, Argentina · 83 sites in all
- Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)Pivotal-lookingCompleted
Eisai Inc.Eisai
NCT00658528 · 1,061 participants · Start Feb 2008 · Primary completion Sep 2009
Drug: Rabeprazole sodium; Esomeprazole · For: Gastroesophageal Reflux Disease (GERD)
Sites: Anaheim, California; Isidro Casanova, La Matanza, Argentina; Ramos Mejía, Argentina · 88 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- chronic kidney disease4,878
- renal failure3,417
- acute kidney injury2,629
- nausea1,646
- drug ineffective1,579
- end stage renal disease1,310
- diarrhoea1,203
- dyspnoea1,196
- pain1,189
- headache1,130
- death1,128
- tubulointerstitial nephritis1,122
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,025 |
| 2005 | 1,068 |
| 2006 | 1,064 |
| 2007 | 958 |
| 2008 | 1,000 |
| 2009 | 914 |
| 2010 | 1,179 |
| 2011 | 1,674 |
| 2012 | 1,874 |
| 2013 | 663 |
| 2014 | 602 |
| 2015 | 712 |
| 2016 | 745 |
| 2017 | 654 |
| 2018 | 5,997 |
| 2019 | 1,359 |
| 2020 | 726 |
| 2021 | 888 |
| 2022 | 1,122 |
| 2023 | 945 |
| 2024 | 892 |
| 2025 | 736 |
| 2026 | 492 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Aciphex (Rabeprazole Sodium)
2024 spending
$16.4M
Beneficiaries
1,549
6,163 claims
Per beneficiary
$10,584
$29.03 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $4,515,854 |
| 2023 | $15,631,965 |
| 2024 | $16,394,805 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency.
Graham DY, Tansel A · Clin Gastroenterol Hepatol 2018 · Comparative Study, Research Support, N.I.H., Extramural
- Vitamin B12 deficiency and use of proton pump inhibitors: a systematic review and meta-analysis.
Choudhury A, Jena A, Jearth V, et al. · Expert Rev Gastroenterol Hepatol 2023 · Meta-Analysis, Systematic Review
- Comparative Efficacy of P-CAB vs Proton Pump Inhibitors for Grade C/D Esophagitis: A Systematic Review and Network Meta-analysis.
Zhuang Q, Chen S, Zhou X, et al. · Am J Gastroenterol 2024 · Systematic Review, Comparative Study
- Proton Pump Inhibitors for Inducing and Maintaining Remission in Eosinophilic Esophagitis: An Updated Systematic Review and Meta-Analysis.
Lucendo AJ, Gutiérrez-Ramírez L, Tejera-Muñoz A, et al. · Clin Gastroenterol Hepatol 2025 · Meta-Analysis, Systematic Review
- Efficacy of Bifidobacterium animalis subsp. lactis BL-99 in the treatment of functional dyspepsia: a randomized placebo-controlled clinical trial.
Zhang Q, Li G, Zhao W, et al. · Nat Commun 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P, Katz PO, Chen Y, et al. · Am J Gastroenterol 2003 · Clinical Trial, Comparative Study
Sponsor: Waylis Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.